<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82252">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847248</url>
  </required_header>
  <id_info>
    <org_study_id>HSPA12B-sepsis-biomarker</org_study_id>
    <nct_id>NCT01847248</nct_id>
  </id_info>
  <brief_title>HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Molecules indicating endothelial injury may serve as biomarkers for severe sepsis
           because of the critical role of endothelial injury in organ dysfunction during severe
           sepsis.

        -  HSPA12B is primarily located in endothelial cells and detectable during sepsis.

        -  The investigators speculated that HSPA12B from endothelial cells might be correlated
           with severe sepsis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>mortality within 28 days after recruitment.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">118</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>sepsis</arm_group_label>
    <description>Patients with sepsis but not severe sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe sepsis</arm_group_label>
    <description>Patients with severe sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIRS</arm_group_label>
    <description>Patients with SIRS after major orthopedics surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Continuous patients with sepsis, severe sepsis, SIRS after major orthopedics surgery and
        healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Patients meet the diagnostic criteria according to the grouping

        Exclusion Criteria:

          -  patients without informed consent

          -  patients who were undergoing continuous renal replacement therapy before sampling

          -  patients with special infection induced by virus, tubercle bacillus, mycoplasma,
             Chlamydia, and so on
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke-ming Zhu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Jia-feng Wang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>biomarker</keyword>
  <keyword>HSPA12B</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
